This study indicated the relationship between TBC1D23 expression and the adverse clinicopathological characteristics of patients with NSCLC, suggesting that TBC1D23 may be an important target for NSCLC treatment. This evidence concerns the gene TBC1D23 and non-small cell lung carcinoma.